Delving into the Latest Updates on Centro Nacional de Investigaciones Oncologicas with Synapse

概览

疾病领域	数量

肿瘤	1
免疫系统疾病	1
血液及淋巴系统疾病	1

排名前五的药物类型	数量

小分子化药	1
腺相关病毒基因治疗	1

排名前五的靶点	数量

PIM1(Pim-1 激酶)	1

关联

5

项与 Centro Nacional de Investigaciones Oncologicas 相关的药物

AAV9-tert gene therapy (CNIO/Universitat Autonoma de Barcelona/F Hoffmann-La Roche)

靶点-

作用机制

基因转移

在研机构

F. Hoffmann-La Roche Ltd. [+2]

原研机构

Centro Nacional de Investigaciones Oncologicas

在研适应症

再生障碍性贫血 [+2]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

IBL-100

靶点

PIM1

作用机制

PIM1抑制剂

在研机构

Centro Nacional de Investigaciones Oncologicas [+1]

原研机构

Centro Nacional de Investigaciones Oncologicas

在研适应症

自身免疫性疾病 [+2]

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

Salermide

靶点

SIRT1 x SIRT2

作用机制

SIRT1抑制剂 [+1]

在研机构-

原研机构

Centro Nacional de Investigaciones Oncologicas

在研适应症-

非在研适应症

肿瘤

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Centro Nacional de Investigaciones Oncologicas 相关的临床结果

登录后查看更多信息

0 项与 Centro Nacional de Investigaciones Oncologicas 相关的专利（医药）

登录后查看更多信息

3,042

项与 Centro Nacional de Investigaciones Oncologicas 相关的文献（医药）

2025-12-31·OncoImmunology

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers

Article

作者: Díez-Alonso, Laura ; Álvarez-Vallina, Luis ; Arroyo-Ródenas, Javier ; Velasco-Sidro, Miriam ; Ramírez-Fernández, Ángel

Despite recent advances in immunotherapy against B cell malignancies such as BCMA (B cell maturation antigen) and CD19-targeted treatments using soluble T cell-engaging (TCE) antibodies or chimeric antigen receptor T cells (CAR-T), there is still an important number of patients experiencing refractory/relapsed (R/R) disease. Approaches to avoid tumor-intrinsic mechanisms of resistance such as immune pressure-mediated antigen downmodulation, are being broadly investigated. These strategies include BCMA/CD19 dual-targeting therapies, which may be of particular interest to patients with B cell lymphoma and multiple myeloma, where a specific double-positive immature subpopulation is commonly associated with poor prognosis and poor response to current treatments. In fact, several clinical trials targeting both antigens through different strategies are currently underway. Here, based on the previously validated STAb (in situ secretion of T cell-redirecting bispecific antibodies) concept, we used two different engineering strategies (pool and co-transduction) to generate dual-targeted STAb-T cells simultaneously secreting BCMA TCE and CD19 TCE that outperformed single-targeted STAb-T cells in different in vitro models. These promising results encourage further preclinical clinical testing of dual STAb-T cells in R/R B-cell malignancies.

2025-07-01·Physiological Reviews

The influence of extracellular vesicles on tumor evolution and resistance to therapy

Review

作者: Bastón, Enrique ; García-Agulló, Juan ; Peinado, Héctor

Disruption of cellular communication that regulates normal physiology is often a key factor in the development of disease, including cancer. Extracellular vesicles (EVs) are mediators of cell-cell communication, modulating local and distant microenvironments and playing an important role influencing tumor progression at both early and late stages. Indeed, EV-mediated communication participates in the initial steps of primary tumor transformation and proliferation as well as the preparation of the premetastatic niche and subsequent metastasis. In this context, the presence of DNA in EVs (EV-DNA) is particularly intriguing, with important biological implications and significant potential as a biomarker in liquid biopsies. In this review we discuss the mechanisms involved in EV-shed DNA and the potential impact in tumor evolution. In addition, it has become apparent in recent years that the secretion of EVs also influences the behavior of the surrounding microenvironment. An important unresolved challenge in oncology is the resistance of tumors to treatment, one of the primary causes of high cancer mortality. The role of EVs in therapy resistance has garnered considerable interest. In the latter part of this review, we also examine the potential involvement of EVs in resistance to therapy.

2025-05-01·Clinical Cancer Research

Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial

作者: Gajate, Pablo ; Rodríguez-Moreno, Juan F. ; Ruiz-Llorente, Sergio ; Fernández, Ricardo ; Rodríguez-Antona, Cristina ; Virizuela, Juan A. ; Graña-Castro, Osvaldo ; Berraondo, Pedro ; Sevillano-Fernández, Elena ; Vázquez, Sergio ; Font, Albert ; García-Donas, Jesús ; de Velasco, Guillermo ; Álvarez-Fernández, Carlos ; Beltrán, Luis ; Lainez, Nuria ; Collado, Ricardo ; Madurga, Rodrigo

AbstractPurpose:Neoadjuvant treatment of bladder cancer is evolving, with immunotherapy demonstrating promising activity. PARP inhibition combined with immune activation has been proposed as a synergistic strategy. We conducted a comprehensive molecular characterization of tumors treated with this combination in the neoadjuvant setting to provide crucial results for rational development.Patients and Methods:A phase II clinical trial was designed to evaluate the combination of anti-PDL1 inhibitor durvalumab and PARP inhibitor olaparib, focusing on biomarker dynamics in both pre- and post-treatment settings. A total of 29 patients were enrolled. Genomic and transcriptomic profiling, as well as analyses of immune cell populations, was conducted at baseline and at the time of cystectomy.Results:Of the 29 patients treated, a pathologic complete response was observed in 13 cases (44.8%). No major safety concerns were associated with the treatment, and 26 patients (90%) underwent cystectomy. Mutational patterns, tumor mutation burden, and homologous recombination deficiency remained stable throughout treatment and were not predictive of outcomes. However, a shift toward stromal phenotypes and increased expression of epithelial–mesenchymal transition signatures were observed following therapy, particularly in resistant tumors. Moreover, an increase in circulating CD4+ CD27− CD28− T cells was noted among responders.Conclusions:The combination of neoadjuvant durvalumab and olaparib shows therapeutic activity in bladder cancer. Resistance mechanisms seem to be driven by transcriptional adaptations rather than the emergence of new mutations.

100 项与 Centro Nacional de Investigaciones Oncologicas 相关的药物交易

登录后查看更多信息

100 项与 Centro Nacional de Investigaciones Oncologicas 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月14日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

1

临床前

其他

3

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

AAV9-tert gene therapy (CNIO/Universitat Autonoma de Barcelona/F Hoffmann-La Roche)	心脏衰竭更多	临床前
IBL-100 ( PIM1 )	炎症更多	药物发现
ETP-46321 ( PI3Kα x PI3Kδ )	肿瘤更多	无进展
Salermide ( SIRT1 x SIRT2 )	肿瘤更多	无进展
ETP-46992 ( Class I PI3K )	肿瘤更多	无进展